14 research outputs found
Algunas consideraciones sobre la adaptación del patrimonio arquitectónico para museo. 29 Tercera época (2019) enero. Hereditas
No full textRossi, Aldo” LA arquitectura de la ciudad”2ª edición ampliada.12 tirada.2013.Gustavo Gilli Edi-tores, 1982.
Del Moral, Enrique Defensa y conservación de las ciudades y conjuntos urbanos monumentales. Academia de las Artes. México, 1980, pp. 26 más ilustraciones.
Huerta, Ricard. La ciudad y sus docentes. Miradas desde el arte de la educación. Barcelona, Edit. UOC. 2015, pp. 207.
Mumford, Lewis. The Culture of Cities. New York, Harvest Book, 1970, pp. 552.
Pérez Ruiz Maya Lorena “La museología participativa:¿tercera vertiente de la museología mexicana? “ en Cucuilco. No. 44, spetiembre-diciembre, 2008. pp. 88-110.
Upton, Dell “The City as Material Culture” en http://www.arthistory.ucla.edu/people/facul-ty/dupton/CITYasMC1r.pdf
Swati Chattopadhyay “Architectural History and Spatial Imagination”, en “Perspectives of History”. enero 2014. Consultado el 18 de Julio de 2015 en http://www.historians.org/publica-tions-and-directories/perspectives-on-history/january-2014/architectural-history-and-spatial-imagination
Upton,Dell “Architectural History or Landscape History?” Journal of Architectural Educa-tion 44, no. 4 (August 1991): 195– 99.
The City as artifact en Encyclopedia of Chicago www.encyclopedia.chicagohistory.org/.../288.html
López Bahut, Emma “La reflexión de Jorge Oteiza sobre el espacio urbano en los años cincuenta. Una posible relectura contemporánea”. en-www.academia.edu/.../La_reflexión_de_Jor-ge_Oteiza_sobre_el_espacio_...Barry Begdoll “Good Neighbors: The Museum of Modern Art and Latin America, 1933-1935, a journey through the MOMA archives”, en Modernidad Urbana .Compiladores: Louise Noelle e Ivan San Martín. Docomomo México, 2012, pp. 41-75.Lefevbre, Henri “La producción del espacio” http://blogs.fad.unam.mx/asignatura/nadia_osornio/wp-content/uploads/2014/05/lefeb-vre-la-produccion-del-espacio.pdf consultado el 24 de julio 2015.Mairesse, Francois y Desvallées André Vers une redefinition du musée? Paris, Editions L ́ Her-mattan, Museologies, 2007, pp. 225.Herreman, Yani “A new canvas for a new creative talent” en Museum International.Onlinelibrary.wiley.com › ... › Museum International › Vol 41 Issue 4.Venturi Robert, Brown, Denise and Steven Ize-nour, Learning from las Vegas.The forgotten symbolism of Architectural Form. Boston, Massachussetts, MIT Press, pp. 208.“Jane Jacobs” en The architectural revue. No. 26 october 2011. en http://www.architectural-review.com/view/reviews/reputations/-jane-ja-cobs-1916-2006/8621634.article consultado el 17 de julio 2015.Silverman, Helaine “Community museums in the San Lorenzo, Tenochtitlan Region, Mexico” en Archeological Site Museums in Latin America, Cultural Heritage Series, University Press of Florida, Boca Raton, Florida, 2006, pp. 30-46.Our Greatest Artefact: the City Essays on cities and museums about them. en http://network.icom.museum/fileadmin/user_upload/minisites/camoc/PDF/CAMOCBookOurGreatestArte-factTheCity.pdf consultado el 10 de Julio de 2015.Mumford, Lewis. Sidewalk Critic.Writings on Ney York. Edited by Robert Wojrowics.Princeton Ar-chitectural Press, New York, 1998
Des écomusées, retour à la définition et évolution
No full textAs ecomuseums are criticized in France, among curators as well as university searcher, the author develops a reflection on the relevance of the ecomuseum concept and its application. In the first part, the nine principles of the «evolving definition» are analysed, which clearly shows that this type is still valid for the present. In the second part, five French ecomuseums, old, new, or in construction are described. Each refers to the same founding texts. For each one the description develops a specific aspect of the evolving definition, which summarizes its character. It appears that it is possible for the concept to be expressed in a rather thorough way. In conclusion, the author says he believes ecomuseums can still be a starting point for reflections and actions in museology.L'auteur propose de réfléchir à la validité du concept d'écomusée et de sa mise en œuvre, dans un contexte général où un tel concept fait l'objet de critiques chez les universitaires et les conservateurs. Une première partie engage une relecture de la définition évolutive des écomusées. Les neufs principes sont soumis un par un à une analyse du texte. De cette analyse il ressort que l'approche développée est encore moderne. Une seconde partie présente des écomusées français, anciens, nouveaux ou en cours de création qui s'appuient sur ces mêmes textes fondateurs. Pour chacun est étudié un thème majeur de la définition évolutive pouvant partiellement en caractériser l'orientation. Ces expériences montrent que l'on peut aller assez loin dans la mise en œuvre du concept. En conclusion, les auteurs estiment que les écomusées peuvent encore être des ferments de la réflexion et de l'action muséale.El autor propone una réflexion acerca de la vigencia del concepto de ecomuseo y de su utilización, dentro de un contexto general en el que fue muy criticado por universitarios y curadores. En la primera parte aborda una revision de la definición evolutiva de los ecomuseos. Los nueve principios son sometidos, uno por uno, a un anâlisis de texto. A partir de este anâlisis concluye que el enfoque desarrollado puede seguir considerandose como moderno. La segunda parte présenta algunos ecomuseos franceses, antiguos, nuevos o en via de création que se apoyan en esos mismos textos fundadores. En cada caso se estudia un tema central de la definición y su evolution. Taies experiencias demuestran que la utilizaciôn del concepto puede aplicarse a casos multiples. En conclusion, el autor estima que los ecomuseos pue- den seguir enriqueciendo la reflexion la acción museistica.Delarge Alexandre. Des écomusées, retour à la définition et évolution. In: Publics et Musées, n°17-18, 2000. L'écomusée : rêve ou réalité (sous la direction de André Desvallées) pp. 139-155
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)
No full textInternational audienceCurrent HIV prophylactic vaccines evaluate HIV Env as purified proteins. CD40.HIVRI.Env is an innovative antigen delivery targeting gp140 Env from HIV Clade C 96ZM651 to CD40-expressing antigen-presenting cells, thus harnessing the intrinsic immune-stimulant properties. DNA-HIV-PT123 vaccine encodes 96ZM651 gp140/Gag and 97CN54 Pol/Nef
At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods
No full textBy September 2022, more than 600 million cases of SARS-CoV-2 infection have been reported globally, resulting in over 6.5 million deaths. COVID-19 mortality risk estimators are often, however, developed with small unrepresentative samples and with methodological limitations. It is highly important to develop predictive tools for pulmonary embolism (PE) in COVID-19 patients as one of the most severe preventable complications of COVID-19. Early recognition can help provide life-saving targeted anti-coagulation therapy right at admission. Using a dataset of more than 800,000 COVID-19 patients from an international cohort, we propose a cost-sensitive gradient-boosted machine learning model that predicts occurrence of PE and death at admission. Logistic regression, Cox proportional hazards models, and Shapley values were used to identify key predictors for PE and death. Our prediction model had a test AUROC of 75.9% and 74.2%, and sensitivities of 67.5% and 72.7% for PE and all-cause mortality respectively on a highly diverse and held-out test set. The PE prediction model was also evaluated on patients in UK and Spain separately with test results of 74.5% AUROC, 63.5% sensitivity and 78.9% AUROC, 95.7% sensitivity. Age, sex, region of admission, comorbidities (chronic cardiac and pulmonary disease, dementia, diabetes, hypertension, cancer, obesity, smoking), and symptoms (any, confusion, chest pain, fatigue, headache, fever, muscle or joint pain, shortness of breath) were the most important clinical predictors at admission. Age, overall presence of symptoms, shortness of breath, and hypertension were found to be key predictors for PE using our extreme gradient boosted model. This analysis based on the, until now, largest global dataset for this set of problems can inform hospital prioritisation policy and guide long term clinical research and decision-making for COVID-19 patients globally. Our machine learning model developed from an international cohort can serve to better regulate hospital risk prioritisation of at-risk patients. © The Author(s) 2024
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
No full textInterindividual clinical vari-ability is vast in humans infected withsevere acute respiratory syndrome corona-virus 2 (SARS-CoV-2), ranging from silent in-fection to rapid death. Three risk factors forlife-threatening coronavirus disease 2019(COVID-19) pneumonia have been identified—being male, being elderly, or having othermedical conditions—but these risk factorscannot explain why critical disease remainsrelatively rare in any given epidemiologicalgroup. Given the rising toll of the COVID-19pandemic in terms of morbidity and mortality,understanding the causes and mechanisms oflife-threatening COVID-19 is crucial.The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, The Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, the Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the French National Research Agency (ANR) under the Investments for the Future program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANRS-COV05), the Square Foundation, Grandir – Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, the Institut Institut National de la Santé et de la Recherche Médicale (INSERM), and the University of Paris. Samples from San Raffaele Hospital were obtained through the Covid-BioB project and by healthcare personnel of San Raffaele Hospital, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) clinical laboratory and clinical research unit, funded by the Program Project COVID-19 OSR-UniSR and Fondazione Telethon. The French COVID Cohort Study Group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). The Milieu Intérieur Consortium was supported by the French Government’s Investissement d’Avenir program, Laboratoire d’Excellence Milieu Intérieur grant (ANR-10-LABX-69-01) (primary investigators: L.Q.-M. and D.Du.). The Simoa experiment was supported by the PHRC-20-0375 COVID-19 grant “DIGITAL COVID” (primary investigator: G.G.). S.G.T. is supported by a Leadership 3 Investigator Grant awarded by the National Health and Medical Research Council of Australia and a COVID19 Rapid Response Grant awarded by UNSW Sydney. C.R.-G. and colleagues were supported by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334, Spanish Ministry of Science and Innovation RTC-2017-6471-1; AEI/FEDER, UE) and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). S.T.-A. and A.B. were supported by ANR-20-COVI-0064 (primary investigator: A.Be.). This work is supported by the French Ministry of Health “Programme Hospitalier de Recherche Clinique Inter regional 2013,” by the Contrat de Plan Etat-Lorraine and FEDER Lorraine, and by a public grant overseen by the French National Research Agency (ANR) as part of the second Investissements d’Avenir program FIGHT-HF (reference no. ANR-15-RHU-0004) and by the French PIA project “Lorraine Université d’Excellence” (reference no. ANR-15-IDEX-04-LUE) (45); and biobanking is performed by the Biological Resource Center Lorrain BB-0033-00035. This study was supported by the Fonds IMMUNOV, for Innovation in Immunopathology; by a grant from the Agence National de la Recherche (ANR-flash Covid19 “AIROCovid” to F.R.-L.); and by the FAST Foundation (French Friends of Sheba Tel Hashomer Hospital). Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1; a George Mason University Fast Grant; and the G. Harold and Leila Y. Mathers Charitable Foundation. The Amsterdam UMC Covid-19 Biobank was supported by grants from the Amsterdam Corona Research Fund, the Dr. C.J. Vaillant Fund, and the Netherlands Organization for Health Research and Development [ZonMw; NWO-Vici-Grant (grant no. 918·19·627 to D.v.d.B.)]. This work was also supported by the Division of Intramural Research of the National Institute of Dental Craniofacial Research and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and by Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e comorbidita”). The opinions and assertions expressed herein are those of the author(s) and do not necessarily reflect the official policy or position of the Uniformed Services University or the Department of Defense. J.H. holds an Institut Imagine M.D.-Ph.D. fellowship from the Fondation Bettencourt Schueller. J.R. is supported by the INSERM Ph.D. program (“poste d’accueil Inserm”). P.Ba. was supported by the French Foundation for Medical Research (FRM, EA20170638020) and the M.D.-Ph.D. program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). We thank the Association “Turner et vous” for their help and support. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. D.C.V. is supported by the Fonds de la recherche en santé du Québec clinician-scientist scholar program. K.K. was supported by the Estonian Research Council grant PUT1367. We thank the GEN-COVID Multicenter Study (https://sites.google.com/dbm.unisi.it/gen-covid). We thank the NIAID Office of Cyber Infrastructure and Computational Biology, Bioinformatics and Computational Biosciences Branch (contract no. HHSN316201300006W/HHSN27200002 to MSC, Inc.), the Operations Engineering Branch for developing the HGRepo system to enable streamlined access to the data, and the NCI Advanced Biomedical Computational Science (ABCS) for data transformation support. Biomedical Advanced Research and Development Authority was supported under contract no. HHSO10201600031C (to J.H.). Financial support was provided by the National Institute of Allergy and Infectious Diseases (NIAID) K08AI135091; the Burroughs Wellcome Fund CAMS; the Clinical Immunology Society; and the American Academy of Allergy, Asthma, and Immunology
O DESAFIO DE INTEGRAÇÃO DAS COMUNIDADES LOCAIS A PARTIR DOS ECOMUSEUS - UMA EXPERIÊNCIA NA AMAZÔNIA PARAENSE
No full textOs Ecomuseus representam uma abordagem museológica inovadora e socialmente justa, enfatizando o protagonismo comunitário e a valorização do patrimônio cultural e ambiental local. Seu conceito sugere um museu vivo, sonoro e participativo, integrado ao território e à comunidade. Destarte, este trabalho tem como objetivo central discordar sobre os desafios para a integração das comunidades locais a partir da análise das experiências desenvolvidas com a criação das primeiras iniciativas inovadoras à museologia comunitária em Belém do Pará, especificamente, com a implantação do Subsistema de Educação e Cultura para o Desenvolvimento Sustentável, que solidificou como bases para a criação do Ecomuseu da Amazônia e do Ecomuseu de Belém, abordando seus desafios e possibilidades. Este trabalho se caracteriza como um relato de experiência, analítico descritivo, apontando para a possibilidade de expansão dos Ecomuseus e sua importância para o fortalecimento e integração comunitária em diferentes aspectos
Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19
No full textIntroduction
Acute kidney injury (AKI) has been identified as one of the most common and significant problems in hospitalized patients with COVID-19. However, studies examining the relationship between COVID-19 and AKI in low- and low-middle income countries (LLMIC) are lacking. Given that AKI is known to carry a higher mortality rate in these countries, it is important to understand differences in this population.
Methods
This prospective, observational study examines the AKI incidence and characteristics of 32,210 patients with COVID-19 from 49 countries across all income levels who were admitted to an intensive care unit during their hospital stay.
Results
Among patients with COVID-19 admitted to the intensive care unit (ICU), AKI incidence was highest in patients in LLMIC, followed by patients in upper-middle income countries (UMIC) and high-income countries (HIC) (53%, 38%, and 30%, respectively), whereas dialysis rates were lowest among patients with AKI from LLMIC and highest among those from HIC (27% vs. 45%). Patients with AKI in LLMIC had the largest proportion of community-acquired AKI (CA-AKI) and highest rate of in-hospital death (79% vs. 54% in HIC and 66% in UMIC). The association between AKI, being from LLMIC and in-hospital death persisted even after adjusting for disease severity.
Conclusions
AKI is a particularly devastating complication of COVID-19 among patients from poorer nations where the gaps in accessibility and quality of healthcare delivery have a major impact on patient outcomes
Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study
No full textin this study we aimed to characterize the type and prevalence of neurological symptoms related to neurological long-COVID-19 from a large international multicenter cohort of adults after discharge from hospital for acute COVID-19
Neurological manifestations of COVID-19 in adults and children
No full textDifferent neurological manifestations of coronavirus disease 2019 (COVID-19) in adults and children and their impact have not been well characterized. We aimed to determine the prevalence of neurological manifestations and in-hospital complications among hospitalized COVID-19 patients and ascertain differences between adults and children. We conducted a prospective multicentre observational study using the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) cohort across 1507 sites worldwide from 30 January 2020 to 25 May 2021. Analyses of neurological manifestations and neurological complications considered unadjusted prevalence estimates for predefined patient subgroups, and adjusted estimates as a function of patient age and time of hospitalization using generalized linear models.
Overall, 161 239 patients (158 267 adults; 2972 children) hospitalized with COVID-19 and assessed for neurological manifestations and complications were included. In adults and children, the most frequent neurological manifestations at admission were fatigue (adults: 37.4%; children: 20.4%), altered consciousness (20.9%; 6.8%), myalgia (16.9%; 7.6%), dysgeusia (7.4%; 1.9%), anosmia (6.0%; 2.2%) and seizure (1.1%; 5.2%). In adults, the most frequent in-hospital neurological complications were stroke (1.5%), seizure (1%) and CNS infection (0.2%). Each occurred more frequently in intensive care unit (ICU) than in non-ICU patients. In children, seizure was the only neurological complication to occur more frequently in ICU versus non-ICU (7.1% versus 2.3%, P < 0.001).
Stroke prevalence increased with increasing age, while CNS infection and seizure steadily decreased with age. There was a dramatic decrease in stroke over time during the pandemic. Hypertension, chronic neurological disease and the use of extracorporeal membrane oxygenation were associated with increased risk of stroke. Altered consciousness was associated with CNS infection, seizure and stroke. All in-hospital neurological complications were associated with increased odds of death. The likelihood of death rose with increasing age, especially after 25 years of age.
In conclusion, adults and children have different neurological manifestations and in-hospital complications associated with COVID-19. Stroke risk increased with increasing age, while CNS infection and seizure risk decreased with age
Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry
No full textBackground: COVID-19 has been associated with a broad range of thromboembolic, ischemic, and hemorrhagic complications (coagulopathy complications). Most studies have focused on patients with severe disease from high-income countries (HICs). Objectives: The main aims were to compare the frequency of coagulopathy complications in developing countries (low- and middle-income countries [LMICs]) with those in HICs, delineate the frequency across a range of treatment levels, and determine associations with in-hospital mortality. Methods: Adult patients enrolled in an observational, multinational registry, the International Severe Acute Respiratory and Emerging Infections COVID-19 study, between January 1, 2020, and September 15, 2021, met inclusion criteria, including admission to a hospital for laboratory-confirmed, acute COVID-19 and data on complications and survival. The advanced-treatment cohort received care, such as admission to the intensive care unit, mechanical ventilation, or inotropes or vasopressors; the basic-treatment cohort did not receive any of these interventions. Results: The study population included 495,682 patients from 52 countries, with 63% from LMICs and 85% in the basic treatment cohort. The frequency of coagulopathy complications was higher in HICs (0.76%-3.4%) than in LMICs (0.09%-1.22%). Complications were more frequent in the advanced-treatment cohort than in the basic-treatment cohort. Coagulopathy complications were associated with increased in-hospital mortality (odds ratio, 1.58; 95% CI, 1.52-1.64). The increased mortality associated with these complications was higher in LMICs (58.5%) than in HICs (35.4%). After controlling for coagulopathy complications, treatment intensity, and multiple other factors, the mortality was higher among patients in LMICs than among patients in HICs (odds ratio, 1.45; 95% CI, 1.39-1.51). Conclusion: In a large, international registry of patients hospitalized for COVID-19, coagulopathy complications were more frequent in HICs than in LMICs (developing countries). Increased mortality associated with coagulopathy complications was of a greater magnitude among patients in LMICs. Additional research is needed regarding timely diagnosis of and intervention for coagulation derangements associated with COVID-19, particularly for limited-resource settings
